Pet amiloide en la esclerosis múltiple

  1. Pytel, Vanesa
Dirigée par:
  1. Jorge Matías-Guiu Guía Directeur/trice
  2. Jordi A. Matías-Guiu Directeur/trice
  3. María Nieves Cabrera Martín Directeur/trice

Université de défendre: Universidad Complutense de Madrid

Fecha de defensa: 30 septembre 2019

Jury:
  1. José Luis Carreras Delgado President
  2. Francisco Grandas Pérez Secrétaire
  3. Alfredo Rodríguez-Antigüedad Zarranz Rapporteur
  4. Mª Rosario Blasco Quílez Rapporteur
  5. Julián Benito León Rapporteur

Type: Thèses

Résumé

Multiple sclerosis (MS) is the most common demyelinating disease and the main cause of non-traumatic neurological disability in young adults. It is a clinically heterogeneous disease, including motor, cognitive and fatigue symptoms. This is the result of a combination of the main pathophysiological processes involved: inflammation, demyelination, axonal damage and neurodegeneration. In recent years, various disease-modifying therapies have been developed, aimed at acting on the immune system, with an anti-inflammatory effect that prevents relapses and slows the progression of disability...